Skip to main content
SpringerLink
Log in

TKI-Therapie der CML − Neue Daten zu Absetzen, Umsetzen und Dosisreduzierung

58. ASH Annual Meeting, 03.−06.12.2016 in San Diego, USA

TKI treatment of CML − new data on termination, adjustment and dose reduction

From the 58th ASH Annual Meeting, 3–6 December 2016 in San Diego, USA

  • Onkologiekongresse
  • Published:
Der Onkologe Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Mahon FX et al (2016) Abstract 787. ASH Annual Meeting and Exposition, San Diego, 3–6 December.

    Google Scholar 

  2. Yeoung D et al (2016) Abstract 939. ASH Annual Meeting and Exposition, San Diego, 3–6 December.

    Google Scholar 

  3. Goldberg SL et al (2016) Abstract 937. ASH Annual Meeting and Exposition, San Diego, 3–6 December.

    Google Scholar 

  4. Baccarani M et al (2009) Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 27(35):6041–6051

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Hochhaus A et al (2013) Onkopedia Leitlinie Chronische Myeloische Leukämie (CML). https://www.onkopedia.com/de/onkopedia/guidelines/chronische-myeloische-leukaemie-cml/@@view/pdf/index.pdf?filename=chronische-myeloische-leukaemie-cml.pdf (Erstellt: Januar 2013). Zugegriffen: 20. Dezember 2016

    Google Scholar 

  6. Copland M et al (2016) Abstract 938. ASH Annual Meeting and Exposition, San Diego, 3–6 December.

    Google Scholar 

  7. Legros L et al (2016) Abstract 788. ASH Annual Meeting and Exposition, San Diego, 3–6 December.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Wissenschaftliche Fachkommunikation, Landwehrstr. 31, 80336, München, Deutschland

    Friederike Klein

Authors
  1. Friederike Klein
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Friederike Klein.

Ethics declarations

Interessenkonflikt

F. Klein erhielt eine Unterstütztung zu den Reisekosten zum 58th ASH Annual Meeting 2016 in San Diego durch Amgen GmbH.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Klein, F. TKI-Therapie der CML − Neue Daten zu Absetzen, Umsetzen und Dosisreduzierung. Onkologe 23, 224–227 (2017). https://doi.org/10.1007/s00761-017-0187-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00761-017-0187-9

Search

Navigation